Overview Dividends

(PHR) Phreesia - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US71944F1066

Scheduling Software, Registration Tools, Payment Processing, Network Content

PHR EPS (Earnings per Share)

EPS Growth (3Y CAGR): 192.14%
EPS Trend (3Y Correlation): 82.8%

PHR Revenue

Revenue Growth (3Y CAGR): 18.75%
Revenue Trend (3Y Correlation): 99.0%

Risk via 10d forecast
Volatility	52.7%
Value at Risk 5%th	81.5%
Relative Tail Risk	-6.00%

Reward TTM
Sharpe Ratio	0.09
Alpha	-13.00

Character TTM
Hurst Exponent	0.592
Beta	1.096
Beta Downside	1.061

Drawdowns 3y
Max DD	68.62%
Mean DD	34.03%
Median DD	36.26%

Description: PHR Phreesia November 13, 2025

Phreesia, Inc. (NYSE: PHR) operates a SaaS-based platform that digitizes front-office workflows for U.S. and Canadian healthcare providers. Its product suite spans online appointment scheduling, patient self-registration, insurance verification, point-of-sale and post-visit payment collection, plus content delivery through mobile apps, self-service tablets, web dashboards and on-site kiosks. The company serves a broad client base-from single-specialty practices to large health systems and life-science firms-leveraging a unified platform to streamline intake, improve revenue cycle efficiency, and enhance patient engagement.

Key recent metrics underscore the business’s growth trajectory: FY 2023 revenue reached $215 million, up 22 % YoY, driven largely by a 35 % increase in subscription ARR from new health-system contracts; gross margin improved to 78 % as the mix shifted toward higher-margin SaaS subscriptions; and net dollar retention exceeded 115 %, reflecting strong upsell and cross-sell activity. Primary economic drivers include accelerating adoption of digital front-end solutions amid rising healthcare spending (projected CAGR 5.5 % through 2028) and payer pressure to reduce administrative costs, while sector-wide trends such as telehealth expansion and value-based care reimbursement models further boost demand for automated intake and revenue-cycle tools.

For a deeper quantitative assessment, you may want to explore the ValueRay platform’s detailed financial models for PHR.

PHR Stock Overview

Market Cap in USD	1,358m
Sub-Industry	Health Care Technology
IPO / Inception	2019-07-18
Return 12m vs S&P 500	-9.56%
Analyst Rating	4.67 of 5

PHR Dividends

Currently no dividends paid

PHR Growth Ratios

CAGR 3y	-3.87%
CAGR/Max DD Calmar Ratio	-0.06
CAGR/Mean DD Pain Ratio	-0.11
Current Volume	747.3k
Average Volume	419.2k

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (-24.1m TTM) > 0 and > 6% of Revenue (6% = 27.0m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 15.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 26.13% (prev 20.24%; Δ 5.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 51.7m > Net Income -24.1m (YES >=105%, WARN >=100%)

Net Debt (-93.5m) to EBITDA (6.85m) ratio: -13.66 <= 3.0 (WARN <= 3.5)

Current Ratio 2.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (59.3m) change vs 12m ago 3.06% (target <= -2.0% for YES)

Gross Margin 72.52% (prev 60.93%; Δ 11.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 116.7% (prev 107.7%; Δ 9.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -10.44 (EBITDA TTM 6.85m / Interest Expense TTM 2.06m) >= 6 (WARN >= 3)

Altman Z'' -12.54

(A) 0.29 = (Total Current Assets 222.6m - Total Current Liabilities 105.1m) / Total Assets 408.6m

(B) -1.97 = Retained Earnings (Balance) -804.8m / Total Assets 408.6m

warn (B) unusual magnitude: -1.97 — check mapping/units

(D) -7.27 = Book Value of Equity -804.0m / Total Liabilities 110.6m

Total Rating: -12.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.93

1. Piotroski 6.0pt = 1.0

2. FCF Yield 2.76% = 1.38

3. FCF Margin 7.76% = 1.94

4. Debt/Equity 0.02 = 2.50

5. Debt/Ebitda -13.66 = 2.50

6. ROIC - WACC (= -20.47)% = -12.50

7. RoE -8.75% = -1.46

8. Rev. Trend 99.00% = 7.42

9. EPS Trend 82.82% = 4.14

What is the price of PHR shares?

As of November 16, 2025, the stock is trading at USD 21.77 with a total of 747,279 shares traded.
Over the past week, the price has changed by -1.14%, over one month by -4.93%, over three months by -22.28% and over the past year by +3.67%.

Is Phreesia a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Phreesia is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 56.93 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PHR is around 18.88 USD . This means that PHR is currently overvalued and has a potential downside of -13.28%.

Is PHR a buy, sell or hold?

Phreesia has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy PHR.

Strong Buy: 10
Buy: 5
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PHR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	33.8	55.3%
Analysts Target Price	33.8	55.3%
ValueRay Target Price	21.3	-2%

PHR Fundamental Data Overview November 01, 2025

Market Cap USD = 1.36b (1.36b USD * 1.0 USD.USD)
P/E Forward = 384.6154
P/S = 3.0192
P/B = 4.5923
Beta = 0.684
Revenue TTM = 449.7m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 6.85m USD
Long Term Debt = 4.58m USD (from longTermDebt, last quarter)
Short Term Debt = 7.10m USD (from shortLongTermDebt, last quarter)
Debt = 4.75m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -93.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.26b USD (1.36b + Debt 4.75m - CCE 98.3m)
Interest Coverage Ratio = -10.44 (Ebit TTM -21.5m / Interest Expense TTM 2.06m)
FCF Yield = 2.76% (FCF TTM 34.9m / Enterprise Value 1.26b)
FCF Margin = 7.76% (FCF TTM 34.9m / Revenue TTM 449.7m)
Net Margin = -5.35% (Net Income TTM -24.1m / Revenue TTM 449.7m)
Gross Margin = 72.52% ((Revenue TTM 449.7m - Cost of Revenue TTM 123.6m) / Revenue TTM)
Gross Margin QoQ = 85.16% (prev 67.17%)
Tobins Q-Ratio = 3.09 (Enterprise Value 1.26b / Total Assets 408.6m)
Interest Expense / Debt = 9.15% (Interest Expense 435.0k / Debt 4.75m)
Taxrate = -100.0% (out of range, set to none) (563.0k / -563.0k)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.12 (Total Current Assets 222.6m / Total Current Liabilities 105.1m)
Debt / Equity = 0.02 (Debt 4.75m / totalStockholderEquity, last quarter 298.0m)
Debt / EBITDA = -13.66 (Net Debt -93.5m / EBITDA 6.85m)
Debt / FCF = -2.68 (Net Debt -93.5m / FCF TTM 34.9m)
Total Stockholder Equity = 274.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.89% (Net Income -24.1m / Total Assets 408.6m)
RoE = -8.75% (Net Income TTM -24.1m / Total Stockholder Equity 274.9m)
RoCE = -7.68% (EBIT -21.5m / Capital Employed (Equity 274.9m + L.T.Debt 4.58m))
RoIC = -10.46% (negative operating profit) (EBIT -21.5m / (Assets 408.6m - Curr.Liab 105.1m - Cash 98.3m))
WACC = 10.01% (E(1.36b)/V(1.36b) * Re(10.05%) + (debt cost/tax rate unavailable))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.57%
[DCF Debug] Terminal Value 61.97% ; FCFE base≈34.9m ; Y1≈22.9m ; Y5≈10.5m
Fair Price DCF = 2.55 (DCF Value 153.0m / Shares Outstanding 59.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 82.82 | EPS CAGR: 192.1% | SUE: 0.13 | # QB: 0
Revenue Correlation: 99.00 | Revenue CAGR: 18.75% | SUE: 0.37 | # QB: 0

Additional Sources for PHR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle